AstraZeneca (AZN) Tops Q4 EPS by 8c

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.21, $0.08 better than the analyst estimate of $1.13. Revenue for the quarter came in at $5.59 billion versus the consensus estimate of $5.57 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• VNET Group (VNET) Misses Q2 EPS by 164c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance